The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Bomedemstat plus momelotinib in patients with myelofibrosis: trial-in-progress
Ciro Rinaldi, MD, PhD, United Lincolnshire Teaching Hospital and University of Lincoln, Lincoln, UK, discusses the upcoming Phase II trial (ISRCTN98283910) that will assess the safety and efficacy of bomedemstat plus momelotinib in patients with myelofibrosis (MF), highlighting the potential benefit of combining JAK inhibition with LSD1 inhibition. Prof. Rinaldi notes that the study aims to determine whether this regimen can increase the number of patients who achieve spleen volume reduction, as well as to assess secondary endpoints, including survival outcomes and markers of disease modification. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I’m very excited this year to present this as a poster presentation. This is a trial in progress, so we are launching the study this year. It’s an interesting combination using two drugs that could potentially work together. Momelotinib is a JAK1/JAK2 inhibitor with also an ACVR1 inhibition effect and bomedemstat an LSD1 inhibitor. The benefit of combining these two drugs is that you have a drug already effective in treating myelofibrosis patients with anemia, and that is momelotinib...
I’m very excited this year to present this as a poster presentation. This is a trial in progress, so we are launching the study this year. It’s an interesting combination using two drugs that could potentially work together. Momelotinib is a JAK1/JAK2 inhibitor with also an ACVR1 inhibition effect and bomedemstat an LSD1 inhibitor. The benefit of combining these two drugs is that you have a drug already effective in treating myelofibrosis patients with anemia, and that is momelotinib. And you have a drug that is potentially a disease modifier because it has an impact on the LSD1 pathway, with a potential effect on megakaryocytes, fibrosis, and potentially changing the environment. There are preclinical data suggesting a potential effect in combining the drug together, and what we’re trying to do with this study is to understand whether the combination of the two molecules might increase the number of patients achieving a spleen improvement, but also there is a number of secondary endpoints that are looking for a more detailed effect on survival, disease-free survival, event-free survival, overall survival, and some additional potential biology effect in terms of reduction of allele burden and disease modification of the myelofibrosis. So it’s very exciting. The study is going to be a phase two. It’s targeting probably 40 patients. It’s going to be international and hopefully we’re going to start in the last quarter of this year.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
